We compared the effectiveness of a 'stepped care' approach with increasing treatment intensity ('Step Care') to one with repeated treatments ('Recycle') among cigarette smokers interested in quitting smoking.
Introduction
A 'stepped care' approach is commonly used in clinical practice for a variety of disease conditions to increase cost-effectiveness by administering more intensive and expensive treatment only to individuals who fail to improve with lower-intensity treatments [1] [2] [3] . Stepped care is based on three assumptions: (1) different people require different levels of care; (2) finding the right level of care often depends on monitoring outcomes and (3) moving from lower to higher levels of care based on patient outcomes increases effectiveness and lowers costs overall [4] . Less intensive interventions are initially tried, with treatment intensification if patients fail to achieve a clinical response. In the case of tobacco dependence treatments, many smokers may benefit from psychosocial interventions (e.g. brief advice or telephone counseling), and therapy can be intensified if smokers fail to achieve smoking abstinence [2] . A 'stepped care' approach could be effectively applied to tobacco dependence [5] .
Although a stepped care model has been presented as a promising approach to treating tobacco dependence [5] [6] [7] [8] [9] , few studies have been conducted evaluating the effectiveness of this approach [2, 10] . The studies that have evaluated this approach have been limited by small sample sizes yielding equivocal results [2, [11] [12] [13] . Only one study evaluated a stepped care approach with an increasing intensity of both pharmacological and behavioral intervention for smokers failing to achieve tobacco abstinence [14] . The authors concluded that stepped care increased smoking cessation in the short-term (3 months) but not long-term (12 months) for patients hospitalized with coronary artery disease. However, this study compared a minimal intervention (brief counseling) to a stepped care approach consisting of brief counseling plus three face-to-face counseling sessions and eight weeks of nicotine patch therapy [14] . Clinical trial evidence demonstrating that a stepped care approach is superior to repeated treatment could significantly advance the treatment of tobacco dependence by providing clinicians more direction in the treatment of smokers who fail to achieve tobacco abstinence with initial interventions.
While there have been very few trials assessing a stepped care approach for smoking cessation [2] , there is evidence to suggest that relapsed smokers are interested in re-engaging in treatment following a relapse [15, 16] . In one study, researchers found that among smokers who had been prescribed a smoking cessation aid but were smoking 3 months later, the majority were interested in trying a reduction strategy (95%), and 82.7% of these individuals were willing to use nicotine replacement therapy (NRT) [17] .
In order to evaluate the efficacy of a stepped care model for smoking cessation compared with repeating the same intervention for cigarette smokers who do not achieve smoking abstinence, we conducted a clinical trial randomizing participants to an intervention with an increasing intensity of behavioral and pharmacologic steps (Step Care) or to an intervention repeating the same treatment strategy (Recycle).
Materials and methods

Study overview
We conducted a randomized, parallel, two-group clinical trial in which individuals were randomized to one of two conditions: (1) Step Care (increasing intensity of intervention) or (2) Recycle (repeated intervention). Prolonged and point prevalence smoking abstinence were assessed at 6, 12, 18, and 24 months after randomization.
Participants
Participants were recruited through advertising and from primary care settings in Memphis, TN between June 2006 and April 2008. For individuals recruited through the primary care setting, potential participants reporting smoking status on clinic intake forms were referred by their clinicians. The project was described to the potential participants, and those still interested were screened for eligibility and consent was obtained. Participants were eligible for recruitment if they were 18 years of age, smoked 10 cigarettes per day (cpd), and were willing to try to stop smoking. A second site in the Midwest was established to recruit participants, but the site was dropped prior to any data analysis due to quality control issues.
Potential participants were excluded if they had: (1) a history of a seizure, brain tumor or head trauma; (2) a history of substance abuse (includes alcohol >21 drinks a week); (3) a history of anorexia/bulimia; (4) a history of unstable cardiovascular disease including: myocardial infarction, stroke and unstable angina in the past six months, or a coronary artery bypass graft or coronary angioplasty/stent in past 3 months; (5) an unstable psychiatric condition or current use of a psychotropic medication including antidepressants; (6) a history of kidney or liver disease; (7) a history of dermatitis; (8) current use of medication that may interfere with primary end points or may increase the risk of side effects from study medication that cannot be discontinued; (9) a history of an allergic reaction to study medications; (10) currently pregnant or breast-feeding; (11) uncontrolled hypertension defined as BP 140/100 mm Hg; or (12) inability to chew gum. The protocol was approved by the Institutional Review Board at UTHSC and registered with ClinicalTrials.gov (NCT00170079).
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Interventions
Interventions were delivered at baseline and at 6 and 12 months after randomization. The behavioral intervention consisted of individual counseling sessions with a trained health educator or counselor. These counseling sessions occurred in our research offices. The behavioral counseling was ½-h in duration and structured with three phases. First, the smokers were taught strategies for preparing to quit such as reducing the number of cpd, breaking the cues related to smoking and engaging in a stop smoking 'ritual' prior to quitting (e.g. removing cigarettes from the house, eliminating ashtrays). Next, participants were encouraged to set a quit date and provided instructions on medication use. Finally, we focused on relapse prevention with identification of high-risk situations and dealing with slips and lapses. Telephone calls were 10-15 min in duration and focused on problem-solving.
Step 1 (baseline)
All participants (Step Care and Recycle) received a behavioral intervention, 6 weeks of the nicotine patch and a counseling telephone call at 7 weeks. The behavioral intervention involved physician advice based upon the 5 A's (ask, advise, assess, assist and arrange) [5] , health educator-delivered behavioral counseling, and telephone counseling. Behavioral counseling consisted of one face-toface individual session covering the topics of preparing for the quit date, reinforcement of nicotine patch use, addressing concerns or misconceptions about patch use, and relapse prevention. The telephone counseling call identified early relapse, provided encouragement and support, and reviewed materials and information provided during the sessions.
The patch dose selected was based upon baseline smoking rate. Participants who reported smoking 20 cpd were initiated on the 21 mg patch and participants who reported smoking 10-19 cpd were initiated on the 14 mg patch. If a participant was initially placed on the 21 mg patch, they used the 21 mg patch for 2 weeks, the 14 mg patch for 2 weeks and the 7 mg patch for 2 weeks. If a participant was initially placed on the 14 mg patch, they used the 14 mg patch for 2 weeks and the 7 mg patch for 4 weeks. Patch use commenced on their quit date.
This step was repeated at 6 and 12 months after randomization with participants in the Recycle group who failed to achieve smoking abstinence.
Step 2 (6 months)
Participants in
Step Care who were smoking at the time of 6-month follow-up received four sessions of in-person behavioral counseling, nine telephone counseling calls, three mailings and bupropion sustained release (SR). Mailings included written information about relapse prevention, tapering medication, identifying high risk situations, developing alternate coping strategies and stress management. Bupropion SR has been found to be superior to placebo [18, 19] and was chosen at the time of trial design as it had been demonstrated to be superior to the nicotine patch alone [20] . Bupropion SR was administered as a 150 mg tablet in the morning for four days. If this dose was well-tolerated, it was increased to 150 mg tablet twice daily. Participants received bupropion for 9 weeks.
The first counseling session was scheduled prior to the participant's quit date and focused on preparing to quit and how to deal with tobacco triggers and craving. The second session was scheduled within 24 h of the quit attempt and addressed support, problem solving and coping with negative emotions. The third session occurred one week post-cessation and emphasized problem solving and building support. The fourth session was scheduled three weeks postcessation and emphasized preventing relapse. The telephone counseling calls identified early relapse, provided encouragement and support, and reviewed materials and information provided during the sessions.
Step 3 (12 months)
Step Care who continued to smoke at 12 months after randomization received six sessions of behavioral counseling, nine telephone counseling calls, three mailings and the nicotine patch
Step Care for tobacco dependence treatment combined with nicotine gum. At the time of the writing of this proposal, the Clinical Practice Guidelines (CPG) suggested that the combined use of NRT products should be used only with patients unable to quit using a single type of pharmacotherapy [21] . Therefore, we elected to use combination NRT after monotherapy with bupropion. The nicotine patch was administered as described above. A maximum of 12 weeks of 4 mg nicotine gum was dispensed, to be taken ad libitum to manage tobacco cravings with a maximum of 12 pieces per day while participants were using the nicotine patch but only after finishing the 21 mg dose. Gum use was assessed at each counseling session to determine the amount to be dispensed for the next week. Available evidence suggested and continues to suggest that patch + gum is more efficacious than the patch alone [19] . Counseling, telephone calls and mailings were similar to the previous steps; however, in Step 3, more time and emphasis was placed on motivational interviewing, which has been shown to augment smoking cessation rates [5] .
Measures
Demographic (e.g. age, race, education) and behavioral measures (self-reported health status) were assessed at baseline. Smoking history was obtained with standard questionnaires. We collected a baseline measure of nicotine dependence with the Fagerström Test for Nicotine Dependence [22] . The primary measure of smoking abstinence was self-reported prolonged abstinence, as recommended by the Society for Research on Nicotine and Tobacco [23] . Self-reports of tobacco use tend to be accurate and misreporting rates are low [24] . Prolonged smoking abstinence was assessed by asking participants if they had smoked ('even a puff') since their target quit date of their most recent quit attempt allowing for a 'grace period' of up to two weeks for smoking lapses. The grace period allowed for lapse (i.e. smoking one cigarette or part of a cigarette) and relapse (i.e. going back to the same rate of smoking as before) during the first two weeks after the self-selected quit date and still meet abstinence criteria at the subsequent followup assessment. The target quit date was set by participants, but participants were encouraged to set a quit date within the first two months of each step. A secondary outcome was point prevalence abstinence, defined as any smoking ('even a puff') in the past seven days. We assessed both 7-day point prevalence and prolonged smoking abstinence at 6, 12, 18, and 24 months after randomization. Abstinence was collected by research staff during research office visits. Adverse events were collected at each follow-up.
Statistical analysis
All analyses were performed with SASv9.4. Baseline statistics, which include means, standard deviations and proportions for demographic data, smoking history and tobacco dependence, were generated for the
Step Care and Recycle conditions. The statistical significance of differences between these respective group means and proportions were assessed for continuous and categorical variables with twosample t-tests and chi-square tests respectively, or their non-parametric counterparts (Wilcoxon Mann-Whitney test and Fishers Exact test) in cases where assumptions were not met. Both univariate and multivariate results are presented for: (1) intention to treat analyses assuming those that dropped out were smokers, (2) study completers only, and for (3) all randomized participants using multiple imputations of the missing values for point prevalence and prolonged abstinence at 6, 12, 18, and 24 months after randomization assuming data were missing at random. We carried out five multiple imputations of the missing outcome values in SAS PROC MI based on the logistic model that included all previously measured and available smoking outcome data at 6, 12, 18, and 24 months after randomization along with demographics, SES variables and tobacco dependence. Each imputed data set was analysed independently, and the results were combined with SAS PROC MIANALYZE to produce appropriate estimates and their variances. Univariate association (unadjusted) between prolonged abstinence (primary outcome) and point prevalence (secondary outcome) and treatment condition was tested with a chi-square test. For prolonged abstinence, this analysis was extended into J. O. Ebbert et al.
a multivariable logistic regression model, adjusting for demographics (age, sex, race, education, marital status and income), self-reported health status and Fagerström Test for Nicotine Dependence scores. Odds ratios and their 95% confidence intervals were estimated and are presented for all analyses to demonstrate the magnitude of the association. Statistical significance was based on two-tailed tests with a type I error rate (alpha) of 0.05%.
We assumed a smoking abstinence rate of 43% for the Step Care condition and 30% for the Recycle condition for the primary end point of prolonged smoking abstinence 18 months after randomization. A sample size of 200 participants per group was determined to provide statistical power (one-tailed, ¼ 0.05) of 80% to detect a difference between treatment groups.
Results
Participants
A total of 1068 individuals were assessed for eligibility among which 798 were excluded (CONSORT Diagram, Fig. 1 ). A total of 270 participants were randomized. Participants had a mean age of 45 years and smoked an average of 23 cpd; 55% were female, 50% were African American (Table I) . Treatment groups were comparable on all collected demographic, smoking, and socioeconomic variables at baseline.
Across both conditions, 185 participants reporting smoking 6 months after randomization and received Step 2 (n recycle ¼ 93, n Step Care ¼92), and 148 participants at 12 months after randomization received Step 3 (n recycle ¼ 76, n Step Care ¼72). 228 participants (84%) returned at 6 months following randomization (n recycle ¼ 110, n Step Care ¼118); 184 participants (68%) returned at 12 months following randomization (n recycle ¼ 89, n Step Care ¼95); 171 participants (63%) returned at 18 months following randomization (n recycle ¼ 86, n Step Care ¼85) and 204 participants returned at 24 months following randomization (n recycle ¼ 100, n Step Care ¼104).
Overall retention rate at 24 months after randomization was 75% (73% in Step Care and 78% in Recycle). At the 24-month time point after randomization, data are unavailable for 27% (n ¼ 38) of Step Care for tobacco dependence treatment participants in the Step Care condition and 22% (n ¼ 28) in the Recycle condition ( 2 ¼ 0.87; df ¼ 1; P ¼ 0.35). Participants lost to follow-up were younger (41.4 versus 46.1 years; P ¼ 0.002) and smoked for fewer years (21.3 versus 25.9; P ¼ 0.002) compared with the study completers. No other significant differences were observed between participants lost to follow-up and completers. Heterogeneity of effect analysis across demographic variables revealed no significant differences.
Smoking abstinence
Table II presents the rates and summary results of the univariate logistic regression analyses for point prevalence and prolonged abstinence at 6, 12, 18, and 24 months after randomization. No significant differences were detected between the Step Care and Recycle groups for point prevalence smoking abstinence. Intention to treat analyses revealed that at 24 months after randomization, the Step Care group appeared to have increased prolonged smoking abstinence to almost twice that of the abstinence achieved in the Recycle group (16.9% versus 9.4%; OR ¼ 1.97, 95% CI 0.94-4.12; P ¼ 0.07). In analyses of completers only, the Step Care group reported prolonged abstinence twice as often as the Recycle group (23.1% versus 12.0%; OR 2.20, 95% CI 1.03-4.69; P ¼ 0.04) at 24 months after randomization.
In both the intention to treat adjusted models and the models that used multiple imputation, there was no statistically significant difference in prolonged abstinence between the groups (Table III) . For study completers at 24 months after randomization, the difference in prolonged abstinence in Step Care was statistically significant in the unadjusted analysis (23.1% versus 12.0%; P ¼ 0.04; see Table II) but not in the adjusted model (P ¼ 0.06; Table III ).
Adverse events
A total of 139 participants reported 293 adverse events during the trial (see Table IV ). Of these adverse events, 132 (40.0%) were rated as mild, 121 (41.3%) were moderate, 38 (12.9%) were severe, and 2 (0.7%) were unknown. Only two (0.6%) were adjudicated as definitely related to study drug with another 29 (9.8%) probably related to study drug. The most common adverse events included skin rash, sleep disturbances, and non-medication related 'pain' and 'injuries.' No significant differences in adverse events were observed between the two groups. The two serious adverse events that occurred were death (myocardial infarction and hypertensive/atherosclerotic cardiovascular disease) and both were in the Step Care group. One participant never received study drug. The other participant had completed the 12-month post-randomization visit and no problems with the nicotine patch were reported. Neither event was adjudicated as being related to study procedures.
Discussion
The results of the current investigation do not clearly demonstrate that a stepped care approach is superior to a repeated intervention for increasing long-term smoking abstinence rates. However, we did not meet our target recruitment. The Step Care intervention was well tolerated and not associated with adverse events.
The stepped care approach employed in the current study provides novel modifications to models proposed and evaluated by previous investigators. Previous investigators had proposed that the initial step of a stepped care approach could consist of a self-help or self-change intervention [6, 8] . In the current study, we provided counseling and NRT as our first intervention. Our approach was intended to inform a clinical practice or referral practice at which many treatment-seeking tobacco users have already exhausted self-help approaches.
Our approach is consistent with CPG [5] which advocate behavioral and pharmacological treatment for all smokers wishing to quit. An investigation of a stepped care approach among hospitalized patients with cardiovascular disease evaluated the effectiveness of offering stepped care with NRT and additional counseling if participants reported smoking after leaving the hospital [14] . In this study, stepped care appeared to increase short-term but Step Care for tobacco dependence treatment not long-term abstinence. Our study evaluated an ambulatory population and provided two rather than one additional steps. Our findings suggest that providers may consider using increasingly aggressive behavioral and pharmacologic interventions for patients who try and fail to stop smoking without increasing the risk for side effects; however, more research is needed to demonstrate clear efficacy.
A Cochrane meta-analysis found that varenicline and combination NRT were superior to NRT monotherapy in promoting smoking abstinence [19] . Recent research has suggested that certain pharmacologic combinations, namely bupropion + varenicline [25] and varenicline + patch [26] are more efficacious then varenicline alone. A review of safety data found that combination therapy does not increase adverse events more than monotherapy [27] , making this an important component in the treatment of tobacco use disorder. However, a recent study found no significant difference in cessation rates between patch, varenicline, or combination patch + lozenge among smokers motivated to quit [28] . Additional data are needed to determine the ideal pharmacologic steps for a stepped care approach in the treatment of tobacco dependence.
Previous studies have found that a stepped care approach is cost-effective for the treatment of alcohol use disorders [2] . If found to be effective, a stepped care approach could be incorporated into tobacco treatment efforts in the primary care and referral tobacco treatment clinical setting. Our Two deaths occurred in the Step Care group, but neither was related to the study treatment. study suggests that a stepped care model could be developed for and disseminated in clinical settings where prescribers and behavioral interventions work in a coordinated fashion. While increasing the intensity of the behavioral intervention may be difficult to achieve in primary care, referrals to commercial smoking cessation programs, tobacco quit lines (1-800-QUITNOW) and internet sites (e.g. smokefree.gov) could potentially augment cessation rates. A larger study could be conducted with varenicline as a component of the pharmacologic steps. Future studies could also investigate the impact of choice on a stepped care approach, evaluations of
Step Care in other settings (e.g. tobacco quit lines), and the cost-effectiveness of such an approach in treating tobacco dependence.
We cannot explain the observed non-statistically significant difference between the two groups at six months which appeared to persist for the rest of the follow-up time points. At 6 months, both groups had received the same intervention. As such, one cannot conclude that any non-statistically significant differences at the later follow-ups are due to the Step Care intervention.
Strengths and limitations
Strengths include the use of the best available evidence to inform both the pharmacologic and behavioral treatment 'steps' at the time the study was conducted [21] as well as the randomized design. Our study was limited by a 25% loss to follow-up rate. However, our study was two years in duration with a lower drop-out than other studies of the nicotine patch and bupropion with a shorter duration of follow-up [20] . In all three adjusted analytical models, the effect size remained similar in magnitude (OR 2).
A limitation to the current study is the research suggesting that bupropion is no more effective than NRT [18] . Because we intended for our pharmacologic 'steps' to be based upon the best available evidence for the most cost-effective and potentially efficacious treatment, the generalizability of our findings are limited with this new information in combination with the release of varenicline. Our generalizability is also limited by the number of exclusion criteria which were required to ensure clinical safety with the provided medications.
Another limitation is that we did not biochemically verify smoking abstinence. Self-reported continuous abstinence was used due to the fact that biochemical verification of smoking status can only assess point prevalence abstinence [29] . Velicer and Prochaska concluded that reports of self-reported smoking were generally valid, unless 'high-demand situations' encouraged under-reporting of tobacco use [30] . Given that our intervention intensified in the Step Care arm, it is possible that some of the participants underreported current smoking, which may limit the validity of our conclusions. The quit date was selected by the participant, and the duration of time between the quit date and the assessment of prolonged abstinence varied by participant at the 6-, 12-, 18-, and 24-month post randomization time points. We did not measure the length of time between the outcome assessment and onset of the quit date following the intervention. As a result, there may be heterogeneity in the duration of prolonged abstinence between the two intervention groups at the assessment time points, the impact of which is likely reduced by the randomized design.
The current design does not allow us to disentangle the effect of intensification of medication therapy from the effect of intensification of the behavioral intervention. A knowledge gap exists as to whether the behavioral or pharmacologic component of Step Care accounts for the increased comparative efficacy or whether both components are needed to increase smoking abstinence rates compared with the recycle condition. If we learn that the behavioral intervention accounts for the increased efficacy, then we can encourage the development of increasingly intensive counseling resources to address smoking relapse. If we learn that pharmacologic therapy accounts for increased efficacy, we should develop medication algorithms to enhance comfort level with combination pharmacotherapy. However, both behavioral and pharmacologic
Step Care for tobacco dependence treatment stepped care approaches may be needed to optimize smoking abstinence. Future investigations should examine the mechanisms of a stepped care approach.
While interventionists met weekly to review clinical cases, we did not collect information on the fidelity of intervention delivery by study staff or on adherence by patients to the intervention. Because of this, it may be difficult to make definitive conclusions about the effectiveness of the stepped care approach in the general population.
Final, while we originally had a second trial recruitment site, quality control issues prevented inclusion of these participants in the data set prior to data analysis. We did not meet our recruitment goals and were underpowered.
Conclusions
Increasing the intensity of behavioral and pharmacologic treatment for smokers who fail to achieve tobacco abstinence with initial therapies is well tolerated. More research is needed to demonstrate clear evidence of efficacy of this approach over repeating the same intervention.
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